2822 indexable Healthcare companies headquartered in England, United Kingdom, ranked by total equity funding and recent funding momentum. Combined disclosed equity funding of $15.3B across 456 funded companies, including 1 unicorn.
| # | Company | Funding | Valuation | Stage | Latest round | Employees | Founded | Momentum |
|---|---|---|---|---|---|---|---|---|
| 1 |
AstraZeneca
Developer of pharmaceutical medicines for oncology and various chronic diseases |
$4.1B | — | Public | Grant (prize money) Jul 2025 | 83,100 | 1999 | ↑ Active |
| 2 |
Biofortuna
Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services |
$21.6M | $476.6M as of 2018 |
Series A | Grant (prize money) Feb 2026 | 32 | 2008 | ↑ Active |
| 3 |
Seda
Provider of consulting services to biopharma sector |
$20M | — | Series B | Series B Mar 2026 | — | 2015 | ↑ Active |
| 4 |
Oxford BioMedica
Manufacturer of viral vectors for cell and gene therapy products |
$149.7M | — | Public | Post IPO Aug 2025 | 815 | 1995 | ↑ Active |
| 5 |
Abingdon Health
Developer of immunoassays for diagnostic purposes |
$24.1M | — | Public | Post IPO Oct 2025 | 151 | 2008 | ↑ Active |
| 6 |
Occuity
Manufacturer of optical instruments for healthcare industry |
$9.4M | — | Seed | Seed Dec 2025 | 41 | 2019 | ↑ Active |
| 7 |
Apex
Manufacturer of fitness equipments |
$4.1M | — | Seed | Seed Jan 2026 | 17 | 2019 | ↑ Active |
| 8 |
Panthera
Clinical trials organization providing site management and patient recruitment services to pharmaceutical and contract research organizations |
$15.9M | — | Late Stage | PE Aug 2025 | 66 | 2019 | ↑ Active |
| 9 |
NRG GYM
Chain of fitness centers |
$7.4M | $16.5M as of 2018 |
Series A | Conventional Debt Oct 2025 | 32 | 2011 | ↑ Active |
| 10 |
Chill Brands Group
Brand of hemp extracts |
$11.6M | — | Public | Post IPO May 2025 | 5 | 2014 | ↑ Active |
| 11 |
Forge Genetics
CRO focused on bioinformatics services |
$3M | — | Seed | Seed Oct 2025 | — | 2023 | ↑ Active |
| 12 |
Lindus Health
Provider of contract based clinical trial & recruitment services |
$23M | — | Series B | Series B Jan 2025 | 7 | 2021 | ↑ Active |
| 13 |
Goodrays
Brand of cannabis gummies, oils, drinks, and other products |
$6.8M | — | Series A | Conventional Debt Jul 2025 | 5 | 2016 | ↑ Active |
| 14 |
Ceryx Medical
Association focusing on developing bioelectronics based on chip technology |
$5.5M | — | Series A | Series A Jun 2025 | 4 | 2016 | ↑ Active |
| 15 |
Medik8
Provider of premium skincare products and personalized skincare regimens |
$55.1M | — | Acquired | Unattributed Jul 2024 | 100 | 1999 | ↑ Active |
| 16 |
Punto Health
Platform facilitating continuous support for patients, families, and providers to manage alzheimer's and other dementias |
$700.7K | — | Seed | Seed Dec 2025 | — | 2023 | ↑ Active |
| 17 |
Cosi Care
Provider of itch relief products for eczema and other skin conditions |
$1M | — | Seed | Seed Nov 2025 | — | 2019 | ↑ Active |
| 18 |
AWAKN
CRO focused on early stage clinical trial research |
$5.9M | — | Acquired | Post IPO Mar 2025 | 3 | 2020 | ↑ Active |
| 19 |
IVC Evidensia
Chains that provide animal veterinary medical care and clinical services |
$4.7B | — | Acquired | Series D May 2021 | 28,000 | 2011 | — |
| 20 |
GPDQ
Online platform booking doctors for house call |
$12M | $5.6M as of 2018 |
Series A | Series A Sep 2024 | 15 | 2015 | ↑ Active |
| 21 |
International SOS
Provider of a digital for protecting global workforces from health and security threats |
$306M | — | Late Stage | Grant (prize money) Dec 2023 | 451 | 1985 | — |
| 22 |
TrueStart Coffee
Provider of specialty coffee, emphasizing health benefits and sustainable practices |
$201K | — | Series A | Series A Jan 2026 | 5 | 2015 | ↑ Active |
| 23 |
PureGym
Chain of fitness centers |
$412.4M | — | Acquired | Conventional Debt Sep 2023 | 3,247 | 2009 | — |
| 24 |
Hexarad
Provider of radiology laboratory center services |
$19.2M | — | Series B | Aug 2024 | 8 | 2016 | ↑ Active |
| 25 |
Until
Provider of fitness and wellness services |
$206.2K | — | Series A | Series A Dec 2025 | 44 | 2019 | ↑ Active |
| 26 |
Tribe
Manufacturer of natural energy protein bars, shakes, and muesli |
$4M | — | Seed | Seed Jan 2025 | 8 | 2015 | ↑ Active |
| 27 |
Magnitude Biosciences
Provider of cell-free in vitro assay for drug discovery companies |
$1M | — | Seed | Grant (prize money) May 2025 | 12 | 2018 | ↑ Active |
| 28 |
VerIQ
Provider of clinical trial services for medical device and health technology |
$134.6K | — | Seed | Seed Jan 2026 | — | 2025 | ↑ Active |
| 29 |
Fallouh Healthcare
Standalone thoracic clinic |
$1M | — | Funding Raised | Grant (prize money) Jun 2025 | 5 | 2015 | ↑ Active |
| 30 |
ImmuONE
CRO focused on innovative solutions for inhalation safety |
$2.4M | — | Seed | Seed Mar 2025 | 8 | 2019 | ↑ Active |
| 31 |
Signify Research
Provider of healthcare technology market intelligence and research services |
$7.8M | — | Series A | Series A Oct 2024 | 29 | 2016 | ↑ Active |
| 32 |
Bridge Farm Bioscience
Provider of cannabis plant research and development company |
$49.2M | $204.7M as of 2024 |
Seed | Seed Apr 2024 | 167 | 2018 | — |
| 33 |
Ennogen
Pharmaceutical and medical device company manufacturing API |
$37.5M | — | Funding Raised | Conventional Debt May 2024 | — | 2011 | — |
| 34 |
Curve Therapeutics
Developer of Microcycle-based therapeutics addressing intracellular targets for cancer and inflammation |
$46.7M | — | Series A | Series A Feb 2024 | 14 | 2019 | — |
| 35 |
Third Space London
Chain of health and fitness clubs |
$108.3M | — | Acquired | Series D Sep 2023 | 87 | 1999 | — |
| 36 |
DP Medical
Supplier of medical equipment and instruments to ENT professionals |
$5.7M | — | Early Stage | Unattributed Aug 2024 | — | 1987 | ↑ Active |
| 37 |
Neupulse
Provider of healthcare management services |
$5.8M | — | Seed | Jul 2024 | 9 | 2021 | ↑ Active |
| 38 |
ScubaTx
Manufacturer of organ preservation devices |
$3.7M | — | Seed | Seed Sep 2024 | 8 | 2020 | ↑ Active |
| 39 |
Paloma
Provider of NHS children’s autism assessments via remote and hybrid pathways |
$2.6M | — | Seed | Seed Nov 2024 | — | 2023 | ↑ Active |
| 40 |
Elder
Marketplace for senior care services |
$18.6M | $12.3M as of 2022 |
Series B | Series B Apr 2024 | 129 | 2015 | — |
| 41 |
PreActiv
Provider of digital perihabilitation programs integrating exercise with multimodal support |
$637.7K | — | Seed | Seed Mar 2025 | 1 | 2020 | ↑ Active |
| 42 |
UCLH
Chain of multi-speciality hospitals |
$205.5M | — | Funding Raised | Grant (prize money) Feb 2022 | 5,573 | 1994 | — |
| 43 |
Ascend
Provider of drug research & development and clinical trial services for cell & gene therapeutic services |
$132.5M | — | Series A | Series A Mar 2023 | 92 | 2021 | — |
| 44 |
MIP Discovery
Provider of nanoparticle design, development & manufacturing services |
$30.6M | — | Series A | Feb 2024 | 32 | 2015 | — |
| 45 |
Prescient Healthcare Group
Consulting services for product strategy and decision support |
$12.7M | $497.5M as of 2024 |
Series B | Series B Jun 2024 | 217 | 2007 | — |
| 46 |
PBR Life Sciences
Provider of market research consulting services for life science sector |
$1.1M | — | Seed | Seed Dec 2024 | — | 2015 | ↑ Active |
| 47 |
One Health Group
Chain of general clinics |
$318K | — | Public | Post IPO Apr 2025 | 45 | 2004 | ↑ Active |
| 48 |
Instil Bio
R&D company developing tumor infiltrating lymphocytes (TIL) for the treatment of solid tumor cancers |
$370.6M | — | Public | Series D Dec 2020 | 23 | 2018 | — |
| 49 |
DeepMirror
Provider of drug research & development, data analysis, and imaging services |
$1.9M | — | Seed | Seed Aug 2024 | 9 | 2019 | ↑ Active |
| 50 |
KBF Enterprises
Development, manufacturing, and distribution of high-quality nutritional products |
$1.7M | — | Funding Raised | Conventional Debt Aug 2024 | 90 | 2007 | ↑ Active |
Developer of pharmaceutical medicines for oncology and various chronic diseases. Research activities focus on the discovery and production of therapeutics targeting cancer, cardiovascular conditions, renal disorders, metabolic diseases, respiratory ailments, and immunological conditions. The business also develops treatments for rare diseases and infectious conditions. Operations involve clinical trials and the appli
Provider of manufacturing services for immunoassays, molecular diagnostics, and regulatory services
Provider of consulting services to biopharma sector
Manufacturer of viral vectors for cell and gene therapy products. Services include process development, analytical methods, and manufacturing support for advanced therapy developers. Expertise spans lentivirus, adeno-associated virus, and adenovirus platforms to facilitate the development and production of therapeutic treatments.
Developer of immunoassays for diagnostic purposes. It offers a rapid lateral flow immunoassay system that enables multiplexed immunodiagnostics. Its flagship product Seralite- FLC measures kappa (K) and lambda (λ) immunoglobulin-free light chain used for the detection of hematological cancers. It als provide research services for a range of sectors including the clinical point of care, clinical self-test, pharmaceut
Manufacturer of optical instruments for healthcare industry
Manufacturer of fitness equipments
Panthera Bio is a clinical trials organization that provides dedicated clinical trial sites in the UK, delivering clinical trials and patient recruitment services to pharmaceutical and contract research organizations. The company aims to transform the North Texas Biotechnology industry by offering efficient R&D and validation services, ensuring rapid development and accelerated timelines. With a focus on patient recr
Chain of fitness centers
Brand of hemp extracts
CRO focused on bioinformatics services. It helps clients maintain their intellectual property while enabling high-precision gene knockouts and insertions. The company operates primarily as a contract research organization offering strain development services and aims to expand its technology into cell and gene therapy applications.
Provider of contract based clinical trial & recruitment services
Rankings are computed by Radar (Fliar BI) from the Radar company master and are updated periodically. Funding and momentum scores use disclosed equity-funding data only. Figures may lag private rounds. Last updated 2026-06-16.
